Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
NRTINucleoside Reverse Transcriptase Inhibitor (therapy)
NRTINeighborhood Reinvestment Training Institute
NRTINukleosidische Reverse Transkriptase Inhibitoren (German: Nucleoside Reverse Transcriptase Inhibitors; AIDS therapy)
NRTINational Retail Traffic Index (ShopperTrak)
NRTINatural Resources Training Institute (Bhutan)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Unlike previous studies which excluded participants with known resistance participants in this study with prior resistance to NRTIs, NNRTIs and/or protease inhibitors could enroll.
Hastalara Baslanan Antiretrovital Tedavi Rejimleri Antiretroviral Tedavi Rejimleri Sayi (%) 2 NRTI + INI 97 (49.5) 2 NRT + NNRTI 16 (8.2) 2 NRTI + PI 83 (42.3) NRTI: nukleozid revers transkriptaz inhibitoru, INI: integraz inhibitoru, NNRTI: nonnukleozid revers transkriptaz inhibitoru, PI: proteaz inhibitoru.
In the NEAT 001/ANRS 143 study (21), DRV/r and RAL were found to be non-inferior to standard therapy with DRV/r and TDF/FTC at 96 weeks (21) although, in individuals with baseline CD4 <200 cells/[mm.sup.3], the NRTI sparing regimen was less efficacious (proportion of failure at week 96 43.2% c.f.
NRTI opened its doors to the first batch of 103 students from 20 states of India, in two fully-residential undergraduate courses - BSc.
3TC, lamivudine; 95% CI, 95% confidence interval; ABC, abacavir; AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; ATV/r, ritonavir-boosted atazanavir; CDC, Center for Disease Control (USA); df, degrees of freedom; EFZ, efavirenz; FPV/r, ritonavir-boosted fosamprenavir; IDV/r, ritonavir-boosted indinavir; IQR, interquartile range; LPV/r, ritonavir-boosted lopinavir; NNRTI, non-nucleoside analog reverse transcriptase inhibitor; NRTI, nucleoside analog reverse transcriptase inhibitor; NVP, nevirapine; OR, odds ratio; p, p-value; PI, protease inhibitor; SD, standard deviation; TDF, tenofovir; W, Mann-Whitney test statistic; [X.sup.2], chi-squared test statistic.
It is significant that approximately a third of the participants (34.3%) had received only one previous ART regimen (RTV- or LPV/r-based first-line ART, including single-drug substitutions from RTV to LPV/r, a single NRTI switch, or temporary 3TC monotherapy) before starting on the DRV/r-, RAL- or ETR-containing regimen, which was effectively a second-line ART regimen for these participants.
ART combinations were included; zidovudin/lamivudine or tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine in NRTI class, nevirapine or efavirenz in NNRTI class, lopinavir/ritonavir or darunavir/ritonavir in PI class, raltegravir, dolutegravir or elvitegravir/cobicistat in INI class [5].
Predictor variables were sociodemographic characteristics (age at ART start, sex, marital status, city of residence, and occupation category); factors related to health care system utilization (referral center of attendance, mean number of medical visits per year, time between HIV diagnosis and ART initiation, and registration of hospitalization); clinical and laboratory data (T-CD4+ lymphocyte count and viral load at ART start and recording of AIDS-defining illness before first ART prescription); and first ART regimen, classified into two categories: combination of two nucleoside transcriptase inhibitors (NRTIs) and a nonnucleoside transcriptase inhibitor (NNRTI) and two NRTIs and a ritonavir- (RTV-) boosted or unboosted protease inhibitor (PI).
For the last two decades the standard for treating HIV infection is a three-drug protocol: "two nukes and a third drug." The "two nukes" are nucleoside reverse transcriptase inhibitors (NRTI) and DNA chain terminators, like AZT (azidothymidine--Retrovir, which is also a NRTI).
Cumulative genotype results performed prior to or at the same time of PhenoSense testing found the presence of M184V mutation in 25%, any nucleoside reverse transcriptase inhibitor (NRTI) mutation in 60%, any non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation in 53%, and any protease inhibitor (PI) mutation in 44%.
Logistic regression was used to determine the influence of markers of inflammation, endothelial dysfunction and prothrombotic state, SCORE (combined influence of classical cardiovascular risk factors), use of PI or NRTI, CD4 cell count and viral load on [CIMT.sub.>0.8mm] and presence of carotid plaques.